SynthesisScientific reports2022
Pseudocirrhosis and portal hypertension in patients with metastatic cancers: a systematic review and meta-analysis.
Synthesis in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- [Research progress on pseudocirrhosis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024Pooled it
- Colorectal Surgery in Patients with Liver Cirrhosis: A Systematic Review.World journal of surgery · 2023Pooled it
- Management of parastomal variceal bleeding in an adult with metastatic liver cancer: A case-based review.Radiology case reports · 2026Article
- Ectopic Duodenal Varices Secondary to Portal Hypertension Caused by Primary Hepatic Neuroendocrine Tumor.ACG case reports journal · 2026Article
- Pseudocirrhosis due to liver metastasis from lung squamous cell carcinoma: A case report.Oncology letters · 2026Article
- Diagnostic Pitfalls and Lessons Learned in Portal Hypertension.ACG case reports journal · 2026Article
- Isolated serosal liver infiltration mimicking cirrhosis in gastroesophageal junction adenocarcinoma: A report of 2 cases.Radiology case reports · 2026Article
- Successful reversal of hepatic visceral crisis in HER2-positive metastatic breast cancer: a case report.Frontiers in oncology · 2026Article
- Complete recovery from pseudocirrhosis caused by chemotherapy for diffuse liver metastases of breast cancer.International cancer conference journal · 2025Article
- Article
- Pseudocirrhosis: A Case Series with Clinical and Radiographic Correlation and Review of the Literature.Digestive diseases and sciences · 2024Review
- Imaging findings in malignant hepatic infiltration from neuroendocrine tumor presenting with acute liver failure and mimicking cirrhosis: a case description.Quantitative imaging in medicine and surgery · 2024Article
- Chemotherapy-associated liver morphological changes in hepatic metastases (CALMCHeM).Diagnostic and interventional radiology (Ankara, Turkey) · 2023Article
- A severe case of hypercalcemia in a patient with presumed cryptogenic cirrhosis.Clinical liver diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pseudocirrhosis is a clinical and radiological entity mimicking liver cirrhosis in patients without a history of chronic liver disease. We performed a systematic review and meta-analysis of the current literature to evaluate the state-of-the-art and investigate the epidemiology and clinical features of pseudocirrhosis. We searched PubMed, Web of Science and Scopus for literature published until February 28, 2022. We included in the final analysis 62 articles (N = 389 patients): 51 case reports (N = 64 patients), 5 case series (N = 35 patients) and 6 observational studies (N = 290 patients). About 80% of patients included in the case reports and case series had breast cancer. Most patients had at least one clinical sign of portal hypertension and ascites was the most common clinical manifestation of portal hypertension. The median time from pseudocirrhosis to death was 2 months (IQR 1-7 months). Alkylating agents and antimitotics were the most common classes of anticancer drugs reported in our study population. Notably, about 70% of patients received three or more anticancer drugs. Finally, pseudocirrhosis is a condition that occurs in patients with hepatic metastases and may have a negative impact on survival and clinical management of patients because of the potential development of portal hypertension and its complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.